BRAFV600突变-话题@MedSci

#BRAFV600突变#

7篇内容 | 1051人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2211708, encodeId=77ca2211e089d, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a> <a href='/topic/show?id=4b0e60250e2' target=_blank style='color:#2F92EE;'>#曲美替尼#</a> <a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a> <a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a> <a href='/topic/show?id=597d366685' target=_blank style='color:#2F92EE;'>#BRAFV600突变#</a>, objectTitle=NAT MED | 新辅助帕博利珠单抗、达拉非尼和曲美替尼治疗BRAFV600突变型可切除黑色素瘤：随机2期NeoTrio试验, objectType=article, longId=831797, objectId=aca2831e9782, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240625/1719329214319_6145188.png, objectUrl=/article/show_article.do?id=aca2831e9782, replyNumber=0, likeNumber=88, createdTime=2024-06-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=aca2831e9782, moduleTitle=NAT MED | 新辅助帕博利珠单抗、达拉非尼和曲美替尼治疗BRAFV600突变型可切除黑色素瘤：随机2期NeoTrio试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aca2831e9782)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2027904, encodeId=678d202e9048f, content=<a href='/topic/show?id=597d366685' target=_blank style='color:#2F92EE;'>#BRAFV600突变#</a>, objectTitle=Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗, objectType=article, longId=206683, objectId=000c20668335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=000c20668335, replyNumber=0, likeNumber=78, createdTime=2021-07-06, rootId=0, userName=ycmayy, userId=c805395, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=000c20668335, moduleTitle=Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=000c20668335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027905, encodeId=3486202e90513, content=<a href='/topic/show?id=597d366685' target=_blank style='color:#2F92EE;'>#BRAFV600突变#</a>, objectTitle=Lancet oncol：BRAFv600突变ctDNA可作为黑色素瘤靶向治疗预后的独立预测生物标志物, objectType=article, longId=207182, objectId=7bde20e182c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bde20e182c5, replyNumber=0, likeNumber=64, createdTime=2021-07-30, rootId=0, userName=ycmayy, userId=c805395, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bde20e182c5, moduleTitle=Lancet oncol：BRAFv600突变ctDNA可作为黑色素瘤靶向治疗预后的独立预测生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bde20e182c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027902, encodeId=0871202e902c2, content=<a href='/topic/show?id=597d366685' target=_blank style='color:#2F92EE;'>#BRAFV600突变#</a>, objectTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, objectType=article, longId=149597, objectId=26f714959eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26f714959eaf, replyNumber=0, likeNumber=81, createdTime=2019-05-30, rootId=0, userName=ycmayy, userId=c805395, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26f714959eaf, moduleTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26f714959eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027903, encodeId=3c74202e90371, content=<a href='/topic/show?id=597d366685' target=_blank style='color:#2F92EE;'>#BRAFV600突变#</a>, objectTitle=JCO：Dabrafenib联合Trametinib对BRAFV600突变Ⅲ期黑色素瘤患者无复发生存有益, objectType=article, longId=152422, objectId=77eb15242261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77eb15242261, replyNumber=0, likeNumber=99, createdTime=2018-12-02, rootId=0, userName=ycmayy, userId=c805395, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77eb15242261, moduleTitle=JCO：Dabrafenib联合Trametinib对BRAFV600突变Ⅲ期黑色素瘤患者无复发生存有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77eb15242261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027900, encodeId=2f24202e900e7, content=<a href='/topic/show?id=597d366685' target=_blank style='color:#2F92EE;'>#BRAFV600突变#</a>, objectTitle=JCO：Dabrafenib和Trametinib治疗局部晚期或转移性BRAFV600突变甲状腺未分化癌, objectType=article, longId=118188, objectId=f3d911818880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3d911818880, replyNumber=0, likeNumber=77, createdTime=2018-06-30, rootId=0, userName=ycmayy, userId=c805395, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3d911818880, moduleTitle=JCO：Dabrafenib和Trametinib治疗局部晚期或转移性BRAFV600突变甲状腺未分化癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3d911818880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027899, encodeId=8bf0202e8996c, content=<a href='/topic/show?id=597d366685' target=_blank style='color:#2F92EE;'>#BRAFV600突变#</a>, objectTitle=J NATL CANCER I：BRAFV600突变非黑色素肿瘤的共存基因改变可影响生存？, objectType=article, longId=110934, objectId=a69711093460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a69711093460, replyNumber=0, likeNumber=78, createdTime=2018-06-24, rootId=0, userName=ycmayy, userId=c805395, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a69711093460, moduleTitle=J NATL CANCER I：BRAFV600突变非黑色素肿瘤的共存基因改变可影响生存？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a69711093460)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027901, encodeId=0114202e90149, content=<a href='/topic/show?id=597d366685' target=_blank style='color:#2F92EE;'>#BRAFV600突变#</a>, objectTitle=全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述, objectType=article, longId=122007, objectId=8d8a12200e1b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d8a12200e1b, replyNumber=0, likeNumber=84, createdTime=2018-04-08, rootId=0, userName=ycmayy, userId=c805395, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d8a12200e1b, moduleTitle=全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d8a12200e1b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRAFV600突变

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#黑色素瘤# #曲美替尼# #达拉非尼# #帕博利珠单抗# #BRAFV600突变#

NAT MED | 新辅助帕博利珠单抗、达拉非尼和曲美替尼治疗BRAFV600突变型可切除黑色素瘤：随机2期NeoTrio试验

2024-06-26发表于上海

ycmayy (审核中...)

前往app查看评论内容

#BRAFV600突变#

Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗

2021-07-06

ycmayy (审核中...)

前往app查看评论内容

#BRAFV600突变#

Lancet oncol：BRAFv600突变ctDNA可作为黑色素瘤靶向治疗预后的独立预测生物标志物

2021-07-30

ycmayy (审核中...)

前往app查看评论内容

#BRAFV600突变#

Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤

2019-05-30

ycmayy (审核中...)

前往app查看评论内容

#BRAFV600突变#

JCO：Dabrafenib联合Trametinib对BRAFV600突变Ⅲ期黑色素瘤患者无复发生存有益

2018-12-02

ycmayy (审核中...)

前往app查看评论内容

#BRAFV600突变#

JCO：Dabrafenib和Trametinib治疗局部晚期或转移性BRAFV600突变甲状腺未分化癌

2018-06-30

ycmayy (审核中...)

前往app查看评论内容

#BRAFV600突变#

J NATL CANCER I：BRAFV600突变非黑色素肿瘤的共存基因改变可影响生存？

2018-06-24

ycmayy (审核中...)

前往app查看评论内容

#BRAFV600突变#

全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述

2018-04-08

科室
- - 订阅+
  - 更多科室
工具
服务